EBMT 2024 | Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni
• 15 Apr 2024
Gloria Iacoboni, MD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, outlines some novel immunotherapeutic approaches showing promise in the treatment of patients with lymphoma in the real-world setting. These include tafasitamab plus lenalidomide, the antibody-drug conjugate loncastuximab tesirine, and a triplet combination of polatuzumab, rituximab and bendamustine. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
